Surgery Partners, Inc. (NASDAQ:SGRY) Insider Sells $1,443,916.60 in Stock

Surgery Partners, Inc. (NASDAQ:SGRY - Get Free Report) insider Harrison R. Bane sold 56,315 shares of the firm's stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $25.64, for a total transaction of $1,443,916.60. Following the sale, the insider now directly owns 107,037 shares in the company, valued at $2,744,428.68. The trade was a 34.47 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Surgery Partners Stock Up 1.7 %

NASDAQ:SGRY traded up $0.44 during trading hours on Thursday, hitting $25.79. 685,428 shares of the company's stock traded hands, compared to its average volume of 1,541,284. Surgery Partners, Inc. has a twelve month low of $19.50 and a twelve month high of $35.29. The company has a debt-to-equity ratio of 0.99, a quick ratio of 1.66 and a current ratio of 1.80. The stock's fifty day moving average price is $21.99 and its two-hundred day moving average price is $26.84. The firm has a market cap of $3.28 billion, a P/E ratio of -53.73, a P/E/G ratio of 17.77 and a beta of 2.60.

Surgery Partners (NASDAQ:SGRY - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported $0.19 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.25 by ($0.06). Surgery Partners had a positive return on equity of 2.85% and a negative net margin of 2.03%. The company had revenue of $770.40 million during the quarter, compared to analyst estimates of $768.99 million. During the same period in the previous year, the company posted $0.15 earnings per share. The company's quarterly revenue was up 14.3% on a year-over-year basis. On average, research analysts expect that Surgery Partners, Inc. will post 0.71 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Surgery Partners

A number of hedge funds and other institutional investors have recently bought and sold shares of SGRY. KBC Group NV boosted its position in Surgery Partners by 31.8% in the 3rd quarter. KBC Group NV now owns 2,385 shares of the company's stock valued at $77,000 after buying an additional 576 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. boosted its position in shares of Surgery Partners by 747.6% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,831 shares of the company's stock worth $124,000 after purchasing an additional 3,379 shares during the last quarter. Creative Planning bought a new position in shares of Surgery Partners in the 3rd quarter worth $258,000. Versor Investments LP bought a new position in shares of Surgery Partners in the 3rd quarter worth $271,000. Finally, MeadowBrook Investment Advisors LLC boosted its position in shares of Surgery Partners by 16.6% in the 4th quarter. MeadowBrook Investment Advisors LLC now owns 10,280 shares of the company's stock worth $218,000 after purchasing an additional 1,460 shares during the last quarter.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on SGRY shares. Macquarie reissued an "outperform" rating and set a $34.00 price objective on shares of Surgery Partners in a research report on Tuesday, November 19th. JPMorgan Chase & Co. reduced their target price on Surgery Partners from $38.00 to $28.00 and set a "neutral" rating on the stock in a research report on Tuesday, December 3rd. Bank of America initiated coverage on Surgery Partners in a research note on Monday, December 16th. They issued a "buy" rating and a $30.00 target price for the company. Finally, Royal Bank of Canada lowered their price objective on Surgery Partners from $49.00 to $35.00 and set an "outperform" rating for the company in a research note on Wednesday, November 20th. One analyst has rated the stock with a sell rating, three have given a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, Surgery Partners has a consensus rating of "Moderate Buy" and a consensus target price of $36.56.

Surgery Partners Company Profile

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.